U.S. Software Stock News

Paylocity Holding (PCTY) has drawn fresh attention after a period of mixed share performance, with a small gain over the past month contrasting with weaker moves over the past three months and the past year. See our latest analysis for Paylocity Holding. The recent 7-day share price return of 7.25% and 1-day move of 3.90% come after a weaker patch, with the 1-year total shareholder return of a 41.49% decline indicating that momentum has been fading over the longer term. If this shift in...

Why Warner Bros. Discovery Is On Investors’ Radar Today Warner Bros. Discovery (WBD) is drawing fresh attention after a stretch of mixed share performance, including negative moves over the past week, month, and past 3 months, alongside a positive 1 year total return. See our latest analysis for Warner Bros. Discovery. The recent softness in Warner Bros. Discovery’s share price, including a year-to-date share price return of a 5.4% decline, contrasts with a very large 1-year total shareholder...

In late April 2026, Fiverr International Ltd. reported past first-quarter results showing revenue of US$105.49 million, slightly below last year, while net income rose to US$8.56 million and diluted EPS from continuing operations increased to US$0.23. The company also reiterated full-year 2026 revenue guidance and lifted its profit outlook as it pivots toward higher-value, AI-supported projects and larger client engagements, even as marketplace revenue and active buyers softened. Next, we'll...

If you are wondering whether Collegium Pharmaceutical's current share price reflects its underlying worth, starting with a clear look at value can help frame your next move. The stock last closed at US$34.32, with returns of 5.6% over the past week, 6.2% over the past month, a 24.6% decline year to date, and 24.1% over the past year. Taken together, this gives you a mixed picture of recent performance. Recent coverage around Collegium has focused on its position in the pharmaceuticals space...

FDA grants expanded access to Revolution Medicines' RAS(ON) inhibitor daraxonrasib for metastatic pancreatic cancer prior to formal approval. Expanded access allows eligible patients to receive the therapy outside clinical trials while regulatory review is pending. Revolution Medicines plans to submit daraxonrasib for expedited FDA review following positive late stage clinical results. Revolution Medicines, traded as NasdaqGS:RVMD, now sits at the center of a key regulatory and clinical...

In late April 2026, O’Reilly Automotive reported first-quarter sales of US$4,560.54 million and net income of US$604.18 million, with diluted EPS rising to US$0.72, and raised its full-year guidance while planning 225–235 net new store openings and continuing large-scale share repurchases. The company’s updated outlook, including projected 2026 revenue of US$18.70–US$19.00 billion and operating income margins of 19.3–19.8%, highlights management’s confidence in balancing growth investments...

If you are wondering whether Universal Display at around US$96 per share still offers value, the key is to look past the headline share price and focus on what different valuation lenses are saying. The stock is down about 32.0% over the last year and 20.9% year to date, even though the past month shows a 7.4% gain after a softer 2.7% move over the last week. Recent coverage has focused on Universal Display’s position in the semiconductor space and how investors are weighing its long term...

If you are wondering whether Aramark’s current share price reflects its true value, the next sections walk through what the numbers actually say about the stock. Aramark shares last closed at US$44.95, with returns of 5.6% over 30 days, 22.9% year to date and 35.2% over 1 year, which has many investors reassessing both its potential and its risks. Over the past year Aramark has been in the spotlight as investors have tracked its performance and repositioned their expectations for the...

Analyst sentiment turns cautious ahead of earnings Payoneer Global (PAYO) is back in focus after analysts turned more cautious on its upcoming March 2026 quarter, expecting a year over year earnings decline even as revenue is projected to be higher. See our latest analysis for Payoneer Global. At a share price of $5.04, Payoneer Global has a 1 day share price return of 1.20%, a 90 day share price return of 17.38%, and a 1 year total shareholder return of 30.10%. These figures may indicate...

Enovix (ENVX) is back in focus as traders build positions ahead of the May 6 earnings report, with call option activity increasing and attention on its 100% silicon anode batteries for AI wearables and smartphones. See our latest analysis for Enovix. At a share price of $6.77, Enovix has seen a 1 month share price return of 33.79% while the year to date share price return remains at a 14.20% decline, and the 1 year total shareholder return sits at 6.61%. This suggests that recent momentum is...

If you are wondering whether General Motors at around US$75.77 is still offering value after a strong run, the answer depends on how you look at what the market is pricing in today. The stock has had a mixed short term patch, with a 2.9% decline over the last week, a 4.5% gain over the last 30 days, a 6.4% year to date decline, and a 69.0% return over the last year, alongside a 135.1% return over three years and 33.4% over five years. Recent coverage has focused on General Motors as a key...

Goodyear Tire & Rubber (NasdaqGS:GT) has launched its "Fast Is In Us" global campaign to spotlight its premium Eagle performance tires. The campaign is designed to run across major cultural and motorsport events, including high profile races such as Le Mans and marquee occasions like the Kentucky Derby. Goodyear aims to reinforce its brand presence in high performance segments and reposition the Eagle line as a premium offering. For investors watching Goodyear at a current share price of...

If you are wondering whether NiSource is still fairly priced after its recent run, or if the market is getting ahead of itself, this article focuses squarely on what you are paying for the stock versus what you are getting. NiSource shares last closed at US$48.08, with returns of 0.2% over 7 days, 1.2% over 30 days, 14.0% year to date and 25.6% over the past year. These figures can influence how investors think about both upside potential and downside risk. Recent coverage has focused on...

Framing Generac Holdings (GNRC) after recent share performance Generac Holdings (GNRC) has drawn fresh attention after a strong run in its share price, with returns over the past week, month, and past 3 months standing out against its recent history. For investors tracking the stock, this recent move sits alongside full year revenue of US$4,326.4m and net income of US$189.0m. These figures help anchor any discussion about what the current valuation might be pricing in. See our latest analysis...

Trade Desk (TTD) is back in focus after announcing new integrations with Pacvue and Skai, as well as a global partnership with DramaBox, while a large shareholder trimmed its position ahead of the upcoming earnings report. See our latest analysis for Trade Desk. The recent integrations with Pacvue, Skai, and DramaBox come after a period where Trade Desk’s 30 day share price return of 9.93% contrasts with a 1 year total shareholder return of a 55.19% decline. This suggests short term momentum...

American Airlines Group recently priced US$1.14 billion in enhanced equipment trust certificates to help finance 32 new and existing aircraft as it continues its fleet modernization program amid higher fuel costs and geopolitical tensions. This financing, alongside proposed governance changes and ongoing shareholder activism ahead of the June 10, 2026 annual meeting, highlights how American is balancing capital needs, board structure, and investor influence at a time of elevated expenses and...

PAMT (PAMT) has just opened Q1 2026 with a trailing twelve month revenue base of about US$598.1 million and a basic EPS loss of US$2.48 per share, setting the stage for another result where the top line is sizeable but profitability remains under pressure. Over recent quarters the company has seen quarterly revenue move from US$182.6 million in Q3 2024 to US$141.3 million in Q4 2025, while quarterly basic EPS shifted from a profit of US$0.11 to a loss of US$1.40. The latest update therefore...

Ingram Micro Holding Corporation has already reported first-quarter 2026 results, with net sales rising to US$13.96 billion and net income to US$98.87 million, alongside higher earnings per share and an increased quarterly dividend of US$0.084 per share. The quarter also underscored how large GPU and AI infrastructure deals, enabled by the Xvantage digital platform, are reshaping the mix of revenue growth and profitability across Ingram Micro’s global operations. With Q1 results boosted by...

ImmunityBio (IBRX) is back on investor radars after reporting a 168% year over year increase in quarterly product revenue, driven by ANKTIVA’s commercial rollout across the US, Europe, Macau, and Saudi Arabia. See our latest analysis for ImmunityBio. Despite the strong ANKTIVA rollout, ImmunityBio’s recent share price return has cooled, with a 7 day share price return of a 4.4% decline and a 30 day share price return of a 2.6% decline. However, the year to date share price return of 252% and...

In the first quarter of 2026, General Electric reported revenue of US$12,392 million, slightly lower net income of US$1,904 million, steady earnings per share, and continued its multi-year US$14.46 billion share repurchase program while securing a US$107.8 million U.S. defense engine contract. Beyond the headline numbers, the combination of expanding aerospace defense work and disciplined capital returns through buybacks highlights how GE is reinforcing its focus as a pure-play aerospace...

Moderna (MRNA) opened 2026 with Q1 results that continue the recent trend of revenue and losses sitting side by side, with trailing 12 month revenue at US$1.9 billion and a basic EPS loss of US$7.25 per share tied to a net loss of US$2.8 billion. Over recent quarters, the company has seen quarterly revenue move between US$108 million and US$1.9 billion with basic EPS ranging from a small profit of US$0.03 per share in Q3 2024 to losses of more than US$2.50 per share in several 2025 quarters,...

In late April 2026, Sunrun announced it had priced a US$584 million securitization of residential solar leases and power purchase agreements, its sixteenth such transaction since 2015, featuring US$584 million of A-rated notes with a 6.30% coupon and improved credit spreads versus its 2025 deals. This financing, backed by nearly 38,706 systems across 19 states, Washington D.C. and Puerto Rico with a weighted average customer FICO of 744, underscores Sunrun’s continued access to large-scale,...

Vanguard Capital Management has disclosed a 7.3% stake in Cencora (NYSE:COR) via a Schedule 13G filing. The filing identifies Vanguard as one of Cencora’s largest institutional holders and classifies the position as being held for investment purposes. Cencora operates as a major player in pharmaceutical distribution and related healthcare services, sitting at the center of drug supply chains that connect manufacturers, pharmacies, and providers. With its scale and logistics capabilities,...

If you are wondering whether CRH at around US$115 a share still offers value, or if most of the easy gains are already behind it, this article focuses squarely on what the current price might mean for you. The stock has delivered a 10.3% return over the past 30 days and 18.4% over the last year, while also showing a 2.2% decline over the past week and an 8.7% decline year to date. Recent headlines around CRH have focused on its position as a major player in construction materials and on how...